Time to diagnosis for a rare disease: managing medical uncertainty. A qualitative study.

Diagnosis delay Interpretive phenomenological analysis Myositis Primary immune deficiency Primary immunodeficiencies Qualitative Rare diseases Uncertainty Uncertainty management theory

Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
14 Aug 2024
Historique:
received: 02 03 2024
accepted: 08 08 2024
medline: 15 8 2024
pubmed: 15 8 2024
entrez: 14 8 2024
Statut: epublish

Résumé

People with a rare disease commonly experience long delays from the onset of symptoms to diagnosis. Rare diseases are challenging to diagnose because they are clinically heterogeneous, and many present with non-specific symptoms common to many diseases. We aimed to explore the experiences of people with myositis, primary immunodeficiency (PID), and sarcoidosis from symptom onset to diagnosis to identify factors that might impact receipt of a timely diagnosis. This was a qualitative study using semi-structured interviews. Our approach was informed by Interpretive Phenomenological Analysis (IPA). We applied the lens of uncertainty management theory to tease out how patients experience, assess, manage and cope with puzzling and complex health-related issues while seeking a diagnosis in the cases of rare diseases. We conducted interviews with 26 people with a rare disease. Ten participants had been diagnosed with a form of myositis, 8 with a primary immunodeficiency, and 8 with sarcoidosis. Time to diagnosis ranged from 6 months to 12 years (myositis), immediate to over 20 years (PID), and 6 months to 15 years (sarcoidosis). We identified four themes that described the experiences of participants with a rare disease as they sought a diagnosis for their condition: (1) normalising and/or misattributing symptoms; (2) particularising by clinicians; (3) asserting patients' self-knowledge; and (4) working together through the diagnosable moment. Managing medical uncertainty in the time before diagnosis of a rare disease can be complicated by patients discounting their own symptoms and/or clinicians discounting the scale and impact of those symptoms. Persistence on the part of both clinician and patient is necessary to reach a diagnosis of a rare disease. Strategies such as recognising pattern failure and accommodating self-labelling are key to diagnosis.

Sections du résumé

BACKGROUND BACKGROUND
People with a rare disease commonly experience long delays from the onset of symptoms to diagnosis. Rare diseases are challenging to diagnose because they are clinically heterogeneous, and many present with non-specific symptoms common to many diseases. We aimed to explore the experiences of people with myositis, primary immunodeficiency (PID), and sarcoidosis from symptom onset to diagnosis to identify factors that might impact receipt of a timely diagnosis.
METHODS METHODS
This was a qualitative study using semi-structured interviews. Our approach was informed by Interpretive Phenomenological Analysis (IPA). We applied the lens of uncertainty management theory to tease out how patients experience, assess, manage and cope with puzzling and complex health-related issues while seeking a diagnosis in the cases of rare diseases.
RESULTS RESULTS
We conducted interviews with 26 people with a rare disease. Ten participants had been diagnosed with a form of myositis, 8 with a primary immunodeficiency, and 8 with sarcoidosis. Time to diagnosis ranged from 6 months to 12 years (myositis), immediate to over 20 years (PID), and 6 months to 15 years (sarcoidosis). We identified four themes that described the experiences of participants with a rare disease as they sought a diagnosis for their condition: (1) normalising and/or misattributing symptoms; (2) particularising by clinicians; (3) asserting patients' self-knowledge; and (4) working together through the diagnosable moment.
CONCLUSIONS CONCLUSIONS
Managing medical uncertainty in the time before diagnosis of a rare disease can be complicated by patients discounting their own symptoms and/or clinicians discounting the scale and impact of those symptoms. Persistence on the part of both clinician and patient is necessary to reach a diagnosis of a rare disease. Strategies such as recognising pattern failure and accommodating self-labelling are key to diagnosis.

Identifiants

pubmed: 39143641
doi: 10.1186/s13023-024-03319-2
pii: 10.1186/s13023-024-03319-2
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

297

Subventions

Organisme : Department of Health and Aged Care, Australian Government
ID : 4-G60XELC.

Informations de copyright

© 2024. The Author(s).

Références

Haendel M, Vasilevsky N, Unni D, Bologa C, Harris N, Rehm H, et al. How many rare diseases are there? Nat Rev Drug Discov. 2020;19(2):77–8.
pubmed: 32020066 pmcid: 7771654 doi: 10.1038/d41573-019-00180-y
Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165–73.
pubmed: 31527858 doi: 10.1038/s41431-019-0508-0
Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet. 2008;371(9629):2039–41.
pubmed: 18555915 doi: 10.1016/S0140-6736(08)60872-7
Marwaha S, Knowles JW, Ashley EA. A guide for the diagnosis of rare and undiagnosed disease: beyond the exome. Genome Med. 2022;14(1):23.
pubmed: 35220969 pmcid: 8883622 doi: 10.1186/s13073-022-01026-w
Priolo M, Tartaglia M. The right to ask, the need to answer - when patients Meet Research: how to cope with Time. Int J Environ Res Public Health. 2023;20(5):4573.
pubmed: 36901584 pmcid: 10002068 doi: 10.3390/ijerph20054573
Evans WR, Rafi I. Rare diseases in general practice: recognising the zebras among the horses. Br J Gen Pract. 2016;66(652):550–1.
pubmed: 27789486 pmcid: 5072891 doi: 10.3399/bjgp16X687625
Llubes-Arrià L, Sanromà-Ortíz M, Torné-Ruiz A, Carillo-Álvarez E, García-Expósito J, Roca J. Emotional experience of the diagnostic process of a rare disease and the perception of support systems: a scoping review. J Clin Nurs. 2022;31(1–2):20–31.
pubmed: 34137096 doi: 10.1111/jocn.15922
Dong D, Chung RY-N, Chan RHW, Gong S, Xu RH. Why is misdiagnosis more likely among some people with rare diseases than others? Insights from a population-based cross-sectional study in China. Orphanet J Rare Dis. 2020;15(1):307.
pubmed: 33115515 pmcid: 7594300 doi: 10.1186/s13023-020-01587-2
Amaya-Uribe L, Rojas M, Azizi G, Anaya JM, Gershwin ME. Primary immunodeficiency and autoimmunity: a comprehensive review. J Autoimmun. 2019;99:52–72.
pubmed: 30795880 doi: 10.1016/j.jaut.2019.01.011
Namsrai T, Parkinson A, Chalmers A, Lowe C, Cook M, Phillips C, et al. Diagnostic delay of myositis: an integrated systematic review. Orphanet J Rare Dis. 2022;17(1):420.
pubmed: 36411487 pmcid: 9677896 doi: 10.1186/s13023-022-02570-9
Janssen LMA, van den Akker K, Boussihmad MA, de Vries E. Which triggers could support timely identification of primary antibody deficiency? A qualitative study using the patient perspective. Orphanet J Rare Dis. 2021;16(1):289.
pubmed: 34187500 pmcid: 8243743 doi: 10.1186/s13023-021-01918-x
Namsrai T, Phillips C, Parkinson A, Gregory D, Kelly E, Cook M et al. Diagnostic delay of sarcoidosis: an integrated systematic review. (under Review). 2024.
Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7(1):86.
pubmed: 34857798 doi: 10.1038/s41572-021-00321-x
Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40(1):24–64.
pubmed: 31953710 pmcid: 7082301 doi: 10.1007/s10875-019-00737-x
Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42(7):1473–507.
pubmed: 35748970 pmcid: 9244088 doi: 10.1007/s10875-022-01289-3
Kirkpatrick P, Riminton S. Primary immunodeficiency diseases in Australia and New Zealand. J Clin Immunol. 2007;27(5):517–24.
pubmed: 17588141 doi: 10.1007/s10875-007-9105-z
European Society for Immune Deficiencies. ESID Registry Network Reporting Tool. ESID Registry [Internet]. 2023 30 January 2024 [cited 2024 30 January]. https://cci-reporting.uniklinik-freiburg.de/#/
Ishimura M, Takada H, Doi T, Imai K, Sasahara Y, Kanegane H, et al. Nationwide survey of patients with primary immunodeficiency diseases in Japan. J Clin Immunol. 2011;31(6):968–76.
pubmed: 21956496 doi: 10.1007/s10875-011-9594-7
Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27(5):497–502.
pubmed: 17577648 doi: 10.1007/s10875-007-9103-1
Anderson JT, Cowan J, Condino-Neto A, Levy D, Prusty S. Health-related quality of life in primary immunodeficiencies: impact of delayed diagnosis and treatment burden. Clin Immunol. 2022;236:108931.
pubmed: 35063670 doi: 10.1016/j.clim.2022.108931
Shillitoe B, Bangs C, Guzman D, Gennery AR, Longhurst HJ, Slatter M, et al. The United Kingdom Primary Immune Deficiency (UKPID) registry 2012 to 2017. Clin Exp Immunol. 2018;192(3):284–91.
pubmed: 29878323 pmcid: 5980391 doi: 10.1111/cei.13125
Slade CA, Bosco JJ, Binh Giang T, Kruse E, Stirling RG, Cameron PU, et al. Delayed diagnosis and complications of predominantly antibody deficiencies in a cohort of Australian adults. Front Immunol. 2018;9:694.
pubmed: 29867917 pmcid: 5960671 doi: 10.3389/fimmu.2018.00694
Sève P, Pacheco Y, Durupt F, Jamilloux Y, Gerfaud-Valentin M, Isaac S et al. Sarcoidosis: a clinical overview from symptoms to diagnosis. Cells. 2021;10(4).
Arkema EV, Cozier YC. Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors. Curr Opin Pulm Med. 2020;26(5):527–34.
pubmed: 32701677 pmcid: 7755458 doi: 10.1097/MCP.0000000000000715
Rybicki BA, Major M, Popovich J Jr., Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145(3):234–41.
pubmed: 9012596 doi: 10.1093/oxfordjournals.aje.a009096
Brashers DE. Communication and uncertainty management. J Communication. 2001;51:477–97.
doi: 10.1111/j.1460-2466.2001.tb02892.x
Meyer AND, Giardina TD, Khawaja L, Singh H. Patient and clinician experiences of uncertainty in the diagnostic process: current understanding and future directions. Patient Educ Couns. 2021;104(11):2606–15.
pubmed: 34312032 doi: 10.1016/j.pec.2021.07.028
Scott IA, Doust JA, Keijzers G, Wallis KA. Coping with uncertainty in clinical practice: a narrative review. Med J Aust. 2023;218(9):418–25.
pubmed: 37087692 doi: 10.5694/mja2.51925
Ghosh AK, Joshi S. Tools to manage medical uncertainty. Diabetes Metabolic Syndrome: Clin Res Reviews. 2020;14(5):1529–33.
doi: 10.1016/j.dsx.2020.07.055
Helou MA, DiazGranados D, Ryan MS, Cyrus JW. Uncertainty in decision making in Medicine: a scoping review and thematic analysis of conceptual models. Acad Med. 2020;95(1):157–65.
pubmed: 31348062 pmcid: 6925325 doi: 10.1097/ACM.0000000000002902
Bylund CL, Peterson EB, Cameron KA. A practitioner’s guide to interpersonal communication theory: an overview and exploration of selected theories. Patient Educ Couns. 2012;87(3):261–7.
pubmed: 22112396 doi: 10.1016/j.pec.2011.10.006
Smith JA, Shinebourne P. Interpretative phenomenological analysis. APA handbook of research methods in psychology, Vol 2: Research designs: Quantitative, qualitative, neuropsychological, and biological. APA handbooks in psychology
Larkin M, Flowers P, Smith JA. Interpretative phenomenological analysis: theory, method and research. Interpretative Phenomenological Anal. 2021:1–100.
Biggerstaff D, Thompson AR. Interpretative Phenomenological Analysis (IPA): a qualitative methodology of choice in Healthcare Research. Qualitative Res Psychol. 2008;5(3):214–24.
doi: 10.1080/14780880802314304
George P, Alison R, Joanna S. Interpretive phenomenological analysis applied to healthcare research. Evid Based Nurs. 2019;22(1):7.
doi: 10.1136/ebnurs-2018-103017
QSR International. Nvivo qualitative data analysis software(Version 12) 2020. https://www.qsrinternationalcom/nvivo-qualitative-data-analysis-software/home
Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–57.
pubmed: 17872937 doi: 10.1093/intqhc/mzm042
Lincoln YS, Guba EG. Naturalistic inquiry. Beverly Hills, Calif: Sage; 1985.
doi: 10.1016/0147-1767(85)90062-8
Budych K, Helms TM, Schultz C. How do patients with rare diseases experience the medical encounter? Exploring role behavior and its impact on patient–physician interaction. Health Policy. 2012;105(2):154–64.
pubmed: 22464590 doi: 10.1016/j.healthpol.2012.02.018
Taruscio D, Salvatore M, Lumaka A, Carta C, Cellai LL, Ferrari G, et al. Undiagnosed diseases: needs and opportunities in 20 countries participating in the undiagnosed diseases Network International. Front Public Health. 2023;11:1079601.
pubmed: 36935719 pmcid: 10017550 doi: 10.3389/fpubh.2023.1079601
Cooke G, Valenti L, Glasziou P, Britt H. Common general practice presentations and publication frequency. Aus Fam Physician. 2013;42(1/2):65–8.
Australian Bureau of Statistics. Asthma [Internet], Canberra ABS. 2020-21 Canberra2023 [ https://www.abs.gov.au/statistics/health/health-conditions-and-risks/asthma/latest-release
Nijrolder I, van der Windt D, de Vries H, van der Horst H. Diagnoses during follow-up of patients presenting with fatigue in primary care. CMAJ. 2009;181(10):683–7.
pubmed: 19858240 pmcid: 2774363 doi: 10.1503/cmaj.090647
Stone L. Reframing chaos: a qualitative study of GPs managing patients with medically unexplained symptoms. Aus Fam Physician. 2013;42(7):1–7.
Bösner S, Abushi J, Feufel M, Donner-Banzhoff N. Diagnostic strategies in general practice and the emergency department: a comparative qualitative analysis. BMJ open. 2019;9(5):e026222–e.
pubmed: 31154305 pmcid: 6549708 doi: 10.1136/bmjopen-2018-026222
Coia P, Morley S. Medical reassurance and patients’ responses. J Psychosom Res. 1998;45(5):377–86.
pubmed: 9835230
Pincus T, Holt N, Vogel S, Underwood M, Savage R, Walsh DA, et al. Cognitive and affective reassurance and patient outcomes in primary care: a systematic review. Pain. 2013;154(11):2407–16.
pubmed: 23872104 doi: 10.1016/j.pain.2013.07.019
Levine DM, Mehrotra A. Assessment of diagnosis and triage in validated case vignettes among nonphysicians before and after internet search. JAMA Netw open. 2021;4(3):e213287–e.
pubmed: 33779741 pmcid: 8008286 doi: 10.1001/jamanetworkopen.2021.3287

Auteurs

Christine Phillips (C)

School of Medicine and Psychology, Australian National University, 54 Mills Road, Canberra, 2601, ACT, Australia.

Anne Parkinson (A)

Department of Health Economics, Wellbeing and Society, National Centre for Epidemiology and Population Health, Australian National University, 63 Eggleston Road, Canberra, ACT, 2601, Australia. anne.parkinson@anu.edu.au.

Tergel Namsrai (T)

Department of Health Economics, Wellbeing and Society, National Centre for Epidemiology and Population Health, Australian National University, 63 Eggleston Road, Canberra, ACT, 2601, Australia.

Anita Chalmers (A)

Department of Health Economics, Wellbeing and Society, National Centre for Epidemiology and Population Health, Australian National University, 63 Eggleston Road, Canberra, ACT, 2601, Australia.
Myositis Association Australia, 14/10 Albany Lane, Berry, NSW, 2535, Australia.

Carolyn Dews (C)

Department of Health Economics, Wellbeing and Society, National Centre for Epidemiology and Population Health, Australian National University, 63 Eggleston Road, Canberra, ACT, 2601, Australia.
Immune Deficiencies Foundation Australia, Suite 9, 104 Crown Street, Wollongong, NSW, 2500, Australia.

Dianne Gregory (D)

Department of Health Economics, Wellbeing and Society, National Centre for Epidemiology and Population Health, Australian National University, 63 Eggleston Road, Canberra, ACT, 2601, Australia.
Sarcoidosis Australia, Sydney, NSW, 2000, Australia.

Elaine Kelly (E)

Department of Health Economics, Wellbeing and Society, National Centre for Epidemiology and Population Health, Australian National University, 63 Eggleston Road, Canberra, ACT, 2601, Australia.
Sarcoidosis Australia, Sydney, NSW, 2000, Australia.

Christine Lowe (C)

Department of Health Economics, Wellbeing and Society, National Centre for Epidemiology and Population Health, Australian National University, 63 Eggleston Road, Canberra, ACT, 2601, Australia.
Immune Deficiencies Foundation Australia, Suite 9, 104 Crown Street, Wollongong, NSW, 2500, Australia.

Jane Desborough (J)

Department of Health Economics, Wellbeing and Society, National Centre for Epidemiology and Population Health, Australian National University, 63 Eggleston Road, Canberra, ACT, 2601, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH